Paul Fields

Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

Nita Agar, Emma Wedgeworth, Siobhan Crichton et al. · Journal of Clinical Oncology · 2010 · 845 citations

Medicine, Dermatology, Oncology +17

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin, Adam G. Laing, Miguel Muñoz‐Ruiz et al. · The Lancet Oncology · 2021 · 612 citations · Full text

Veterinary Medicine, Immunology, Oncology +14

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma

N. George Mikhaeel, Martin Hutchings, Paul Fields et al. · Annals of Oncology · 2005 · 407 citations · Full text

Medicine, Oncology, Chemotherapy +11

Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

Stephen Schey, Paul Fields, J. Blake Bartlett et al. · Journal of Clinical Oncology · 2004 · 313 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL

N. George Mikhaeel, Daniel Smith, Joel Dunn et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 312 citations · Full text

Medicine, Biostatistics, Oncology +17